Representative experience
We represented the petitioner in a challenge to an FCC order regarding eligibility for bidding credits in a spectrum auction.
We represented a pharmaceutical company in a challenge to FDA’s denial of orphan drug exclusivity.
We represented the intervenor in a challenge to FERC's approval of a natural gas facility.
We represented the plaintiff in a challenge to CMS's decision to reimburse a biologic as a multiple source drug.
We have represented many pharmaceutical companies in challenges to FDA’s administrative decisions, including denials of various types of exclusivity and approvals of generic drugs.
